Total Payments
$1.1M
2024 Payments
$425,527
Companies
43
Transactions
1,653
Medicare Patients
17,699
Medicare Billing
$1.4M
Payment Breakdown by Category
Research$519,149 (46.2%)
Other$435,776 (38.8%)
Consulting$80,827 (7.2%)
Travel$59,672 (5.3%)
Food & Beverage$27,804 (2.5%)
Education$825.84 (0.1%)
Gifts$250.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $519,149 | 35 | 46.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $435,471 | 157 | 38.7% |
| Consulting Fee | $80,827 | 25 | 7.2% |
| Travel and Lodging | $59,672 | 209 | 5.3% |
| Food and Beverage | $27,804 | 1,198 | 2.5% |
| Education | $825.84 | 26 | 0.1% |
| Honoraria | $305.30 | 2 | 0.0% |
| Gift | $250.00 | 1 | 0.0% |
Payments by Type
General
$605,155
1,618 transactions
Research
$519,149
35 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Nielsen BioSciences, Inc. | $434,061 | 4 | $0 (2024) |
| Amgen Inc. | $122,615 | 208 | $0 (2024) |
| GENZYME CORPORATION | $100,009 | 97 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $97,414 | 112 | $0 (2024) |
| Celgene Corporation | $93,869 | 119 | $0 (2019) |
| Dermavant Sciences, Inc. | $77,132 | 100 | $0 (2024) |
| Galderma Laboratories, L.P. | $61,407 | 160 | $0 (2024) |
| Eli Lilly and Company | $49,374 | 24 | $0 (2024) |
| Allergan, Inc. | $32,240 | 88 | $0 (2022) |
| ABBVIE INC. | $20,630 | 169 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $425,527 | 253 | Nielsen BioSciences, Inc. ($285,406) |
| 2023 | $89,676 | 235 | Dermavant Sciences, Inc. ($36,708) |
| 2022 | $72,974 | 207 | Amgen Inc. ($21,631) |
| 2021 | $46,098 | 183 | Amgen Inc. ($15,350) |
| 2020 | $8,646 | 123 | Amgen Inc. ($3,145) |
| 2019 | $102,091 | 176 | Celgene Corporation ($36,012) |
| 2018 | $117,883 | 235 | GENZYME CORPORATION ($36,958) |
| 2017 | $261,409 | 241 | Nielsen BioSciences, Inc. ($134,471) |
All Payment Transactions
1,653 individual payment records from CMS Open Payments — Page 1 of 67
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $230.48 | General |
| Category: Inflammation | ||||||
| 12/24/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $36.73 | General |
| Category: Inflammation | ||||||
| 12/24/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: Inflammation | ||||||
| 12/24/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $7.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,989.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $187.99 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $32.59 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $107.37 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $5.18 | General |
| 12/10/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $76.02 | General |
| 12/10/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,685.05 | General |
| 12/04/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: Immunology | ||||||
| 12/03/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $1.45 | General |
| 11/30/2024 | Nielsen BioSciences, Inc. | Candin (Biological) | — | Cash or cash equivalent | $285,405.91 | Research |
| Study: CFW-3A • Category: Immunotherapy | ||||||
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $17.16 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $4.59 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $13.80 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CFW-3A | Nielsen BioSciences, Inc. | $285,406 | 1 |
| CFW-2D | Nielsen BioSciences, Inc. | $148,655 | 3 |
| EFFICACY AND SAFETY OF ADAPALENE 0.35BENZOYL PEROXIDE 2.5 GEL PLUS DOXYCYCLINE IN SEVERE INFLAMMATORY ACNE NON-NODULOCYSTIC SUBJECTS | Galderma Laboratories, L.P. | $35,423 | 2 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $20,727 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $18,687 | 3 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $7,406 | 3 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,381 | 6 |
| A PHASE 2 RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP PLACEBO-CONTROLLED 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $447.50 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $374.90 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis. | Allergan Inc. | $373.80 | 6 |
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $149.75 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $15.08 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 3,082 | 13,172 | $816,504 | $282,767 |
| 2022 | 26 | 3,784 | 6,862 | $754,121 | $311,187 |
| 2021 | 28 | 5,067 | 9,118 | $726,384 | $420,571 |
| 2020 | 34 | 5,766 | 10,394 | $777,783 | $427,078 |
Total Patients
17,699
Total Services
39,546
Medicare Billing
$1.4M
Procedure Codes
110
All Medicare Procedures & Services
110 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 705 | 976 | $168,652 | $79,811 | 47.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 236 | 324 | $154,325 | $36,397 | 23.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 423 | 506 | $101,250 | $35,173 | 34.7% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 35 | 71 | $39,050 | $21,767 | 55.7% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 51 | 90 | $40,500 | $16,576 | 40.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 462 | 523 | $78,450 | $15,756 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 270 | 296 | $35,567 | $14,531 | 40.9% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 31 | 7,800 | $15,600 | $10,148 | 65.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 100 | 100 | $20,700 | $9,941 | 48.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 157 | 171 | $30,780 | $9,354 | 30.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 348 | 1,995 | $59,850 | $8,525 | 14.2% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 62 | 74 | $18,500 | $6,120 | 33.1% |
| 15789 | Chemical peel of deep layer of skin of face | Office | 2023 | 15 | 15 | $13,500 | $5,396 | 40.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 27 | 29 | $6,670 | $2,302 | 34.5% |
| 10120 | Removal of foreign body from tissue, accessed beneath the skin, simple | Office | 2023 | 18 | 18 | $4,896 | $1,908 | 39.0% |
| 11303 | Shaving of skin growth of body, arms, or legs, more than 2.0 cm | Office | 2023 | 14 | 21 | $5,250 | $1,838 | 35.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 40 | 51 | $5,100 | $1,779 | 34.9% |
| 11307 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $4,500 | $1,625 | 36.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $3,720 | $1,442 | 38.8% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 18 | $3,600 | $1,243 | 34.5% |
| 69100 | Biopsy of ear | Office | 2023 | 18 | 21 | $4,494 | $831.39 | 18.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 31 | $1,550 | $302.40 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 629 | 855 | $126,014 | $66,973 | 53.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 459 | 545 | $86,770 | $37,254 | 42.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 224 | 311 | $108,160 | $34,462 | 31.9% |
About Dr. Sandra Johnson, MD
Dr. Sandra Johnson, MD is a MOHS-Micrographic Surgery healthcare provider based in Fort Smith, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1447256102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandra Johnson, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $425,527 received in 2024. These payments were reported across 1,653 transactions from 43 companies. The most common payment nature is "" ($519,149).
As a Medicare-enrolled provider, Johnson has provided services to 17,699 Medicare beneficiaries, totaling 39,546 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 110 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties Dermatopathology, Clinical & Laboratory Dermatological Immunology
- Location Fort Smith, AR
- Active Since 06/27/2005
- Last Updated 08/30/2023
- Taxonomy Code 207ND0101X
- Entity Type Individual
- NPI Number 1447256102
Products in Payments
- Candin (Biological) $434,061
- Otezla (Drug) $206,752
- DUPIXENT (Biological) $104,316
- VTAMA (Drug) $77,128
- DUPIXENT DUPILUMAB INJECTION (Biological) $48,526
- DUPIXENT (Drug) $42,885
- EPIDUO FORTE (Drug) $35,597
- TALTZ (Drug) $8,754
- STELARA (Biological) $8,511
- SOOLANTRA (Drug) $8,344
- Tremfya (Drug) $5,734
- Otezla (Biological) $4,172
- ADBRY (Biological) $1,786
- AKLIEF (Drug) $1,404
- Ozanimod (Drug) $1,067
- TREMFYA (Drug) $1,038
- Humira (Biological) $905.75
- MIRVASO (Drug) $900.00
- SKYRIZI (Biological) $746.25
- COSENTYX (Biological) $685.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.